During the past decade, Cary Dermatology Center, PA conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Cary Dermatology Center, PA" are "Dermatitis, Atopic" (2 trials), "Dermatitis" (1 trials), "Eczema" (1 trials), "Genetic Diseases, Inborn" (1 trials) and "Hypersensitivity" (1 trials). Many other conditions were trialed in "Cary Dermatology Center, PA" in a lesser frequency.

Most popular intervention types in "Cary Dermatology Center, PA" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Abrocitinib 100 mg" (1 trials), "Abrocitinib 200 mg" (1 trials), "Dupilumab" (1 trials), "Injectable Placebo" (1 trials) and "Oral Placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Cary Dermatology Center, PA" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Cary Dermatology Center, PA". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Cary Dermatology Center, PA, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Cary Dermatology Center, PA, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".